Scaling Up of Intermittent Preventive Treatment of Malaria in Pregnancy Using Sulphadoxine-pyrimethamine: Prospects and Challenges

Overview

Journal Matern Child Health J

Specialty Health Services

Date 2010 Apr 29

PMID 20425139

Citations 10

Authors

Wellington Aghoghovwia Oyibo

Chimere Obiora Agomo

Affiliations

Soon will be listed here.

Abstract

Intermittent preventive treatment of malaria during pregnancy with sulphadoxine-pyrimethamine (IPTpSP) is one of the major strategies of malaria control in most African countries where malaria is endemic. The use of sulphadoxine-pyrimethamine (SP) for intermittent preventive treatment of malaria during pregnancy was adopted when proof of its superiority to weekly prophylactic dosing with either chloroquine or pyrimethamine became evident from studies in different malaria endemic countries. The administration of 2 and 3 treatment doses of SP for HIV-negative and HIV-positive pregnant women respectively, given after quickening and at an interval not less than 4 weeks was recommended. The prospects of this control strategy lies on the efficacy of SP, convenient treatment dose and high compliance rate. However, the implementation of this strategy and the efficacy of SP are faced with challenges such as: timing of SP administration, rising levels of parasite resistance to SP in the general population, effect of folate supplementation, adequacy of the recommended doses with regards to malaria endemicity and HIV status, interactions between SP and antiretroviral drugs and low coverage in the bid to scale-up its use. This review highlights the prospects and challenges of scaling up IPTp-SP.

Citing Articles

Sub-microscopic Plasmodium falciparum infections and multiple drug resistant single nucleotide polymorphic alleles in pregnant women from southwestern Nigeria.

Ibekpobaoku A, Oboh M, Faal F, Adeniji E, Ajibaye O, Idowu E BMC Res Notes. 2024; 17(1):129.

PMID: 38725016 PMC: 11083805. DOI: 10.1186/s13104-024-06763-2.

Chloroquine and Sulfadoxine-Pyrimethamine Resistance in Sub-Saharan Africa-A Review.

Roux A, Maharaj L, Oyegoke O, Akoniyon O, Adeleke M, Maharaj R Front Genet. 2021; 12:668574.

PMID: 34249090 PMC: 8267899. DOI: 10.3389/fgene.2021.668574.

The pitfalls of scaling up evidence-based interventions in health.

Zomahoun H, Ben Charif A, Freitas A, Garvelink M, Menear M, Dugas M Glob Health Action. 2019; 12(1):1670449.

PMID: 31575331 PMC: 6781190. DOI: 10.1080/16549716.2019.1670449.

Factors influencing uptake of intermittent preventive treatment of malaria in pregnancy using sulphadoxine pyrimethamine in Sunyani Municipality, Ghana.

Ibrahim H, Maya E, Issah K, Apanga P, George Bachan E, Noora C Pan Afr Med J. 2018; 28:122.

PMID: 29515740 PMC: 5839217. DOI: 10.11604/pamj.2017.28.122.12611.

Molecular determinants of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum in Nigeria and the regional emergence of dhps 431V.

Oguike M, Falade C, Shu E, Enato I, Watila I, Baba E Int J Parasitol Drugs Drug Resist. 2016; 6(3):220-229.

PMID: 27821281 PMC: 5094156. DOI: 10.1016/j.ijpddr.2016.08.004.

References

Sirima S, Sawadogo R, Moran A, Konate A, Diarra A, Yameogo M . Failure of a chloroquine chemoprophylaxis program to adequately prevent malaria during pregnancy in Koupéla District, Burkina Faso. Clin Infect Dis. 2003; 36(11):1374-82. DOI: 10.1086/375077. View

Metz J . Folic acid metabolism and malaria. Food Nutr Bull. 2008; 28(4 Suppl):S540-9. DOI: 10.1177/15648265070284S407. View

van Eijk A, Ayisi J, Kuile F, Slutsker L, Otieno J, Misore A . Implementation of intermittent preventive treatment with sulphadoxine-pyrimethamine for control of malaria in pregnancy in Kisumu, western Kenya. Trop Med Int Health. 2004; 9(5):630-7. DOI: 10.1111/j.1365-3156.2004.01242.x. View

Bzik D, Li W, Horii T, Inselburg J . Molecular cloning and sequence analysis of the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene. Proc Natl Acad Sci U S A. 1987; 84(23):8360-4. PMC: 299542. DOI: 10.1073/pnas.84.23.8360. View

Taylor W, White N . Antimalarial drug toxicity: a review. Drug Saf. 2004; 27(1):25-61. DOI: 10.2165/00002018-200427010-00003. View

Hamel M, Greene C, Chiller T, Ouma P, Polyak C, Otieno K . Does cotrimoxazole prophylaxis for the prevention of HIV-associated opportunistic infections select for resistant pathogens in Kenyan adults?. Am J Trop Med Hyg. 2008; 79(3):320-30. View

Newman R, Parise M, Slutsker L, Nahlen B, Steketee R . Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium falciparum-endemic sub-Saharan Africa. Trop Med Int Health. 2003; 8(6):488-506. DOI: 10.1046/j.1365-3156.2003.01066.x. View

McGready R, Davison B, Stepniewska K, Cho T, Shee H, Brockman A . The effects of Plasmodium falciparum and P. vivax infections on placental histopathology in an area of low malaria transmission. Am J Trop Med Hyg. 2004; 70(4):398-407. View

Happi C, Gbotosho G, Folarin O, Akinboye D, Yusuf B, Ebong O . Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in malaria-infected patients from Nigeria. Acta Trop. 2005; 95(3):183-93. DOI: 10.1016/j.actatropica.2005.06.015. View

10.

Wang P, Read M, Sims P, Hyde J . Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization. Mol Microbiol. 1997; 23(5):979-86. DOI: 10.1046/j.1365-2958.1997.2821646.x. View

11.

Brentlinger P, Behrens C, Micek M . Challenges in the concurrent management of malaria and HIV in pregnancy in sub-Saharan Africa. Lancet Infect Dis. 2006; 6(2):100-11. DOI: 10.1016/S1473-3099(06)70383-8. View

12.

Forna F, McConnell M, Kitabire F, Homsy J, Brooks J, Mermin J . Systematic review of the safety of trimethoprim-sulfamethoxazole for prophylaxis in HIV-infected pregnant women: implications for resource-limited settings. AIDS Rev. 2006; 8(1):24-36. View

13.

Parise M, Ayisi J, Nahlen B, Schultz L, Roberts J, Misore A . Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. Am J Trop Med Hyg. 1998; 59(5):813-22. DOI: 10.4269/ajtmh.1998.59.813. View

14.

Hamer D, Mwanakasale V, MacLeod W, Chalwe V, Mukwamataba D, Champo D . Two-dose versus monthly intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine in HIV-seropositive pregnant Zambian women. J Infect Dis. 2007; 196(11):1585-94. DOI: 10.1086/522142. View

15.

Mount A, Mwapasa V, Elliott S, Beeson J, Tadesse E, Lema V . Impairment of humoral immunity to Plasmodium falciparum malaria in pregnancy by HIV infection. Lancet. 2004; 363(9424):1860-7. DOI: 10.1016/S0140-6736(04)16354-X. View

16.

Hill J, Kazembe P . Reaching the Abuja target for intermittent preventive treatment of malaria in pregnancy in African women: a review of progress and operational challenges. Trop Med Int Health. 2006; 11(4):409-18. DOI: 10.1111/j.1365-3156.2006.01585.x. View

17.

Greenwood B . The use of anti-malarial drugs to prevent malaria in the population of malaria-endemic areas. Am J Trop Med Hyg. 2004; 70(1):1-7. View

18.

Gimnig J, MacArthur J, Mbangombe M, Kramer M, Chizani N, Stern R . Severe cutaneous reactions to sulfadoxine-pyrimethamine and trimethoprim-sulfamethoxazole in Blantyre District, Malawi. Am J Trop Med Hyg. 2006; 74(5):738-43. View

19.

Nahlen B, Akintunde A, Alakija T, Ogunbode O, Edungbola L, Adetoro O . Lack of efficacy of pyrimethamine prophylaxis in pregnant Nigerian women. Lancet. 1989; 2(8667):830-4. DOI: 10.1016/s0140-6736(89)92998-x. View

20.

Challis K, Osman N, Cotiro M, Nordahl G, Dgedge M, Bergstrom S . Impact of a double dose of sulphadoxine-pyrimethamine to reduce prevalence of pregnancy malaria in southern Mozambique. Trop Med Int Health. 2004; 9(10):1066-73. DOI: 10.1111/j.1365-3156.2004.01307.x. View